Idronoxil as an Anticancer Agent: Activity and Mechanisms.

Idronoxil as an Anticancer Agent: Activity and Mechanisms. Curr Cancer Drug Targets. 2020 Jan 02;: Authors: Porter K, Fairlie WD, Laczka O, Delebecque F, Wilkinson J Abstract Idronoxil has been the subject of more than 50 peer reviewed publications over the last two decades. This isoflavone is an intriguing regulator of multiple signal transduction pathways, capable of causing a range of biological effects, including cell cycle arrest, apoptosis, an ability to stimulate the immune system, and inhibition of angiogenesis. These multifaceted actions suggest that idronoxil has the potential to synergize with, or complement, a wide range of cancer therapies. Whilst clinically tested in the past, idronoxil's journey was discontinued as a result of its low bioavailability in humans when administered either intravenously or orally, though strategies to overcome this issue are currently being explored. Here, we summarize the current literature regarding the key cellular targets of idronoxil and the mechanisms by which idronoxil exerts its anticancer effects, laying a new foundation toward giving this unique molecule a second chance at contributing to the future of cancer treatment. PMID: 31899676 [PubMed - as supplied by publisher]
Source: Current Cancer Drug Targets - Category: Cancer & Oncology Authors: Tags: Curr Cancer Drug Targets Source Type: research